In this article, we will be looking at the 3 medical stocks to buy according to Mitchell Blutt’s Consonance Capital. You can see our detailed analysis of these stocks and head directly to 8 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital.
3. United Therapeutics Corporation (NASDAQ:UTHR)
Stake Value of Consonance Capital Management: $29,134,000
Percentage of Consonance Capital Management’s 13F Portfolio: 15.94%
Number of Hedge Fund Holders: 52
United Therapeutics Corporation (NASDAQ:UTHR) operates as a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
United Therapeutics Corporation (NASDAQ:UTHR) has gained 18.40% over the past twelve months. Consonance Capital Management’s stake in United Therapeutics Corporation (NASDAQ:UTHR) at the end of the third quarter of 2021 was $29.13 million.
Out of the 867 hedge funds being tracked by Insider Monkey, United Therapeutics Corporation (NASDAQ:UTHR) was a part of 52 hedge fund portfolios by the end of the third quarter of 2021, up from 45 positions in the prior quarter. The total stakes of these funds in United Therapeutics Corporation (NASDAQ:UTHR) were in excess of $2.17 billion.
2. Globus Medical, Inc. (NYSE:GMED)
Stake Value of Consonance Capital Management: $45,137,000
Percentage of Consonance Capital Management’s 13F Portfolio: 24.7%
Number of Hedge Fund Holders: 37
Globus Medical, Inc. (NYSE:GMED) is a healthcare equipment company that manufactures products for patients with musculoskeletal disorders. By the end of the third quarter of 2021, 37 hedge funds held stakes in Globus Medical, Inc. (NYSE:GMED). This is compared to 35 positions in the second quarter of 2021. The total value of these stakes was $266.75 million, of which $45.13 million was the stake of Mitchell Blutt’s Consonance Capital Management.
This January, UBS analyst Matthew Taylor reiterated his Buy rating and $91 price target on the stock for Globus Medical, Inc. (NYSE:GMED).
1. Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Stake Value of Consonance Capital Management: $58,177,000
Percentage of Consonance Capital Management’s 13F Portfolio: 31.84%
Number of Hedge Fund Holders: 31
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is a medical device company that designs, develops, and markets various products for diabetic individuals in the United States. On January 19, 2022, Wells Fargo analyst Lawrence Biegelsen upgraded Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to Overweight from Equal Weight and gave the stock a $160 price target.
By the end of the third quarter of 2021, 31 hedge funds held stakes in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) worth $287.12 million. Of these stakes, Consonance Capital had invested a hefty $58.17 million in the company which is its top holding and accounts for 31.84% of its investment portfolio.
You can also take a look at 20 Biggest Healthcare Companies By Revenue and 10 Best Healthcare Dividend Stocks.
